Cargando…
Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167827/ https://www.ncbi.nlm.nih.gov/pubmed/35680497 http://dx.doi.org/10.1016/j.ejim.2022.06.004 |
| _version_ | 1784720864294469632 |
|---|---|
| author | Masotti, Luca Cioni, Elisa Grifoni, Elisa Cei, Francesco Tarquini, Roberto |
| author_facet | Masotti, Luca Cioni, Elisa Grifoni, Elisa Cei, Francesco Tarquini, Roberto |
| author_sort | Masotti, Luca |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9167827 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Federation of Internal Medicine. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91678272022-06-07 Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure Masotti, Luca Cioni, Elisa Grifoni, Elisa Cei, Francesco Tarquini, Roberto Eur J Intern Med Letter to the Editor European Federation of Internal Medicine. Published by Elsevier B.V. 2022-09 2022-06-06 /pmc/articles/PMC9167827/ /pubmed/35680497 http://dx.doi.org/10.1016/j.ejim.2022.06.004 Text en © 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Masotti, Luca Cioni, Elisa Grifoni, Elisa Cei, Francesco Tarquini, Roberto Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure |
| title | Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure |
| title_full | Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure |
| title_fullStr | Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure |
| title_full_unstemmed | Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure |
| title_short | Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure |
| title_sort | trends of thrombo-inflammation biomarkers after tocilizumab predict treatment failure better than scores in patients with severe sars-cov2 related respiratory failure |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167827/ https://www.ncbi.nlm.nih.gov/pubmed/35680497 http://dx.doi.org/10.1016/j.ejim.2022.06.004 |
| work_keys_str_mv | AT masottiluca trendsofthromboinflammationbiomarkersaftertocilizumabpredicttreatmentfailurebetterthanscoresinpatientswithseveresarscov2relatedrespiratoryfailure AT cionielisa trendsofthromboinflammationbiomarkersaftertocilizumabpredicttreatmentfailurebetterthanscoresinpatientswithseveresarscov2relatedrespiratoryfailure AT grifonielisa trendsofthromboinflammationbiomarkersaftertocilizumabpredicttreatmentfailurebetterthanscoresinpatientswithseveresarscov2relatedrespiratoryfailure AT ceifrancesco trendsofthromboinflammationbiomarkersaftertocilizumabpredicttreatmentfailurebetterthanscoresinpatientswithseveresarscov2relatedrespiratoryfailure AT tarquiniroberto trendsofthromboinflammationbiomarkersaftertocilizumabpredicttreatmentfailurebetterthanscoresinpatientswithseveresarscov2relatedrespiratoryfailure |